Sfoglia per AUTORE
TORTORA G
Collezione AOU Città della Salute di Torino

  

Items : 10

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2024 Feb 5;10(1):13. doi: 10.1038/s41523-024-00619-5.

2024
AOU Città della Salute di Torino

Caldara A; Fontana A; Haspinger ER; Verderame F; Franco A; Valerio MR; Beano A; Raffaele M; Criscitiello C; Curigliano G; Guarino S; Pedersini R; Strina C; La Verde N; Savastano MC; Fuso P; Paris I; Botticelli A; Carbognin L; Fabi A; Di Leone A; Tortora G; Giannarelli D; Scambia G;

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 Aug 1;42(22):2637-2644. doi: 10.1200/JCO.23.02728. Epub 2024 Jun 12.

2024
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Marmorino F; Moretto R; Prisciandaro M; Tamburini E; Tortora G; Passardi A; Bergamo F; Raimondi A; Ritorto G; Borelli B; Conca V; Ugolini C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Boni L; Galon J; Cremolini C;

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2.

2023
AOU Città della Salute di Torino

Fabi A; Carbognin L; Botticelli A; Paris I; Fuso P; Savastano MC; La Verde N; Strina C; Pedersini R; Guarino S; Curigliano G; Criscitiello C; Raffaele M; Beano A; Franco A; Valerio MR; Verderame F; Fontana A; Haspinger ER; Caldara A; Di Leone A; Tortora G; Giannarelli D; Scambia G;

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2023 Oct 30;9(1):89. doi: 10.1038/s41523-023-00596-1.

2023
AOU Città della Salute di Torino

Fabi A; Carbognin L; Botticelli A; Paris I; Fuso P; Savastano MC; La Verde N; Strina C; Pedersini R; Guarino S; Curigliano G; Criscitiello C; Raffaele M; Beano A; Franco A; Valerio MR; Verderame F; Fontana A; Haspinger ER; Caldara A; Di Leone A; Tortora G; Giannarelli D; Scambia G;

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27.

2022
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; et alii...

When to test fetuses for RASopathies? Proposition from a systematic analysis of 352 multicenter cases and a postnatal cohort. in Genetics in medicine : official journal of the American College of Medical Genetics / Genet Med. 2021 Jun;23(6):1116-1124. doi: 10.1038/s41436-020-01093-7. Epub 2021 Feb 10.

2021
AOU Città della Salute di Torino

Giancotti A; Mattina T; Papi L; Damante G; Mazza T; Radio FC; Pantaleoni F; Versacci P; Mastromoro G; Naretto VG; Grosso E; Zonta A; Donati I; Di Marco C; Romagnoli M; Mangiameli D; Tortora G; Sirchia F; Marozza A; Andreucci E; D'Ambrosio V; Corno S; Daniele P; Pinna V; Di Giosaffatte N; Scott A; Pizzuti A; Laberge AM; Tartaglia M; et alii...

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. in Clinical colorectal cancer / Clin Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. Epub 2021 Jul 18.

2021
ASL Torino 4
AOU Città della Salute di Torino

D'Orazio C; Ficorella C; Petrillo A; Ierino D; Spinelli GP; Roberto M; Zoratto F; Ghidini M; Vitale P; Garajova I; Troiani T; Di Pietro FR; De Galitiis F; Zanaletti N; Tinari N; Morelli C; Giampieri R; De Tursi M; Aimar G; Depetris I; Lombardi P; Keränen SR; Claudia F; Leo S; Dell'Aquila E; Spallanzani A; Zurlo V; Gelsomino F; Nigro O; et alii...

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. in Frontiers in oncology / Front Oncol. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. eCollection 2021.

2021
ASL Torino 4
AOU Città della Salute di Torino

Porzio G; Ficorella C; Ferri C; D'Orazio C; Patruno L; Petrillo A; Aimar G; Zoratto F; Roberto M; Spinelli GP; Garajova I; Vitale P; Zanaletti N; Morelli C; Di Marino P; Di Pietro FR; Depetris I; Giampieri R; Roselló Keränen S; Fulgenzi C; Lombardi P; Zurlo IV; Gelsomino F; Nigro O; Ghidini M; Tortora G; Salvatore L; Filippi R; Venditti O; et alii...

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. in BMC cancer / BMC Cancer. 2020 Jul 22;20(1):683. doi: 10.1186/s12885-020-07169-6.

2020
AOU Città della Salute di Torino

Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C;

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. in BMC cancer / BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Ciuffreda L; Basso M; Catalano V; Bracarda S; Verusio C; Maiello E; Cinieri S; Giuliani F; Tassinari D; Frassineti GL; Spallanzani A; Bonetti A; Tortora G; Scagliotti G; Pinotti G; Tomasello G; Bertolini A; Zaniboni A; Longarini R; Luporini AG; Rimassa L; Di Costanzo F; Cardellino GG; Scartozzi M; Berardi R; Di Donato S; Lonardi S; Tamberi S; Antista M; et alii...